KAI-1455 Uses, Dosage, Side Effects and more
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies have demonstrated that epsilon PKC plays a key role in cytoprotection during periods of ischemia. In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult.
Trade Name | KAI-1455 |
Generic | KAI-1455 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in ischemic reperfusion injury.
How KAI-1455 works
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator. It reduces damage during surgical procedures, such as coronary artery bypass grafting, vascular surgery and pediatric cardiac surgery N.B. begun dosing protein tyrosine phosphatase 1B (PTP1B).